天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> Best practice & research. Clinical endocrinology & metabolism >>article

Real-world value of cabergoline in the treatment of acromegaly

Published:1 July 2024 DOI: 10.1016/j.beem.2024.101887

Abstract

Cabergoline is an ergot derivative long-acting dopamine receptor 2 (DR2) selective agonist administered orally and widely used for the treatment of prolactin-secreting adenomas and Parkinson’s disease. DR2 is expressed in most somatotroph adenomas. In acromegaly, cabergoline is used off-label and its role is limited by the relatively modest efficacy for achieving hormonal remission and thus, it is largely indicated in patients with mild elevation of GH/IGF-I postoperatively. It can be given as monotherapy, usually at a higher weekly dose than usually required to treat prolactinomas, but also as an add-on treatment in patients partially responding to the somatostatin receptor ligands octreotide or lanreotide. IGF-1 normalization with cabergoline can be achieved in about a third of the patients. Low baseline IGF-1 level (below 1.5 x ULN) before cabergoline initiation is a good predictor for remission. Combination treatment with the GH receptor antagonist pegvisomant can also be beneficial. The inexpensive, well-tolerated and convenient oral administration of cabergoline makes it an attractive medical therapy for active acromegaly.

Substances (5)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Cabergoline 81409-90-7 C26H37N5O2 337 suppliers $44.00-$3660.00
Octreotide 79517-01-4 C51H70N10O12S2 308 suppliers $59.00-$1871.10
Lanreotide 108736-35-2 C54H69N11O10S2 221 suppliers Inquiry
IGF-1 41 suppliers Inquiry
Pegvisomant 218620-50-9 C257H383N65O77S6 1 suppliers Inquiry

Similar articles

IF:2.1

Efficacy and safety profile of roflumilast in a real-world experience.

Journal of thoracic disease Aykut Cilli, Halid Bal,etc Published: 1 April 2019
IF:4.7

Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19.

Infectious Diseases and Therapy Takahiro Takazono,?Satoki Fujita,etc Published: 1 August 2024
IF:4.6

Cabergoline: a review of its use in the inhibition of lactation for women living with HIV

Journal of the International AIDS Society Karen J Tulloch, Philippe Dodin,etc Published: 11 June 2019